SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    von der Maase H, Hansen S, Roberts J, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 30683077.
  • 2
    Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994; 12: 22642270.
  • 3
    Sweeney C, Roth B, Kabbinavar F, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006; 24: 34513457.
  • 4
    McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15: 18531857.
  • 5
    Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004; 22: 220228.
  • 6
    Raghavan D. Advanced bladder and urothelial cancers. Eur J Cancer. 2000; 36( Suppl 2): 16.
  • 7
    Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997; 15: 589593.
  • 8
    McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol. 1997; 15: 24492455.
  • 9
    Krege S, Rembrink V, Borgermann CH, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol. 2001; 165: 6771.
  • 10
    Goodin S, Kane M, Rubin E. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004; 22: 20152025.
  • 11
    Kowalski R, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem. 1997; 272: 25342541.
  • 12
    Lee F, Borzilleri R, Fairchild C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001; 7: 14291437.
  • 13
    Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res. 2004; 10: 12891298.
  • 14
    Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003; 21: 18661873.
  • 15
    McDaid H, Mani S, Shen H-J, Muggia F, Sonnichsen D, Horwitz S. Validation of the pharmacodynamics of BMS-247550, an analog of epothilone B, during a phase I clinical study. Clin Can Res. 2002; 8: 20352043.
  • 16
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 17
    Bajorin D, Dodd P, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17: 31733181.
  • 18
    International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party,EORTC Genito-Urinary Group,Australian Bladder Cancer Study Group,National Cancer Institute of Canada Clinical Trials Group,Finnbladder, Norwegian Bladder Cancer Study Group, et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999; 354: 533540.
  • 19
    Grossman H, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859866.
  • 20
    Sweeney CJ, Williams SD, Finch DE, et al. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer. 1999; 86: 514518.
  • 21
    Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001; 92: 29932998.
  • 22
    Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006; 94: 13951401.
  • 23
    Hussain MH, Tangen C, Lara P, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005; 23: 87248729.